VERU INC. Proceeds from Issuance of Debt
VERU INC. (VERU) reported Proceeds from Issuance of Debt of $0 for the 12-month period ending 2024-09-30, per its 10-K filed 2024-12-16.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2024-12-16
- VERU INC. proceeds from issuance of debt for the quarter ending 2024-09-30 was $0.00.
- VERU INC. proceeds from issuance of debt for the quarter ending 2023-09-30 was $0.00.
- VERU INC. proceeds from issuance of debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- VERU INC. proceeds from issuance of debt for fiscal 2023 was $1.43M.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-16 | $0.00 10-K · filed 2024-12-16 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | ||
| 2023-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-16 | $1.43M 10-K · filed 2024-12-16 | |
| 2023-06-30 | $1.43M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |